Should I buy or sell Checkpoint Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares. View CKPT analyst ratings or view top-rated stocks .

What is Checkpoint Therapeutics' stock price target for 2024?

5 brokerages have issued 1-year target prices for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's share price to reach $22.60 in the next year. This suggests a possible upside of 1,214.0% from the stock's current price. View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts .

How have CKPT shares performed in 2024?

Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of the year. Since then, CKPT stock has decreased by 24.9% and is now trading at $1.72. View the best growth stocks for 2024 here .

When is Checkpoint Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CKPT earnings forecast .

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its earnings results on Friday, March, 22nd. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million.

When did Checkpoint Therapeutics' stock split?

Checkpoint Therapeutics's stock reverse split on the morning of Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , PTC Therapeutics (PTCT) , Dynavax Technologies (DVAX) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Aldeyra Therapeutics (ALDX) , Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL) .

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CKPT

Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free CKPT Stock Alerts

$1.72

-0.06 (-3.37%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.68
▼
$1.76
50-Day Range: $1.72
▼
$2.32
52-Week Range: $1.30
▼
$3.62

Volume: 469,215 shs
Average Volume: 547,961 shs
Market Capitalization: $61.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.60

Get Checkpoint Therapeutics alerts:

Checkpoint Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,214.0% Upside
$22.60 Price Target
Short Interest: Bearish
12.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.63
Upright™ Environmental Score
News Sentiment: 0.01
Based on 17 Articles This Week
Insider Trading: Selling Shares
$48,297 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

338th out of 929 stocks

Pharmaceutical Preparations Industry

151st out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
Checkpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Checkpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.22% of the float of Checkpoint Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Checkpoint Therapeutics has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Checkpoint Therapeutics has recently increased by 1.91%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Checkpoint Therapeutics does not currently pay a dividend.
Dividend Growth
Checkpoint Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Checkpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Checkpoint Therapeutics is -0.63.

2.2

News and Social Media Coverage

News Sentiment
Checkpoint Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Checkpoint Therapeutics this week, compared to 1 article on an average week.
Search Interest
15 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,297.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Checkpoint Therapeutics is held by insiders.
Percentage Held by Institutions
Only 22.00% of the stock of Checkpoint Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Checkpoint Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Checkpoint Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Checkpoint Therapeutics Stock (NASDAQ:CKPT)

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CKPT Stock News Headlines

April 15, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Checkpoint Therapeutics, Inc. (CKPT) Investors

April 15, 2024 | prnewswire.com

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 14, 2024 | markets.businessinsider.com

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 12, 2024 | prnewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

April 12, 2024 | prnewswire.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT

April 12, 2024 | markets.businessinsider.com

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

April 12, 2024 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 12, 2024 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 12, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

April 12, 2024 | markets.businessinsider.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 11, 2024 | businesswire.com

Checkpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class Action

April 10, 2024 | markets.businessinsider.com

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

April 10, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 10, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

April 9, 2024 | prnewswire.com

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 9, 2024 | businesswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

April 5, 2024 | prnewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Checkpoint Therapeutics, Inc. and Certain Officers - CKPT

March 29, 2024 | yahoo.com

Checkpoint Streaming: Watch & Stream Online via Netflix

March 24, 2024 | finance.yahoo.com

Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations

March 22, 2024 | finanznachrichten.de

Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 22, 2024 | investorplace.com

CKPT Stock Earnings: Checkpoint Therapeutics Misses EPS, Misses Revenue for Q4 2023

March 22, 2024 | globenewswire.com

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 18, 2024 | msn.com

DUI Checkpoint Planned For Canyon Lake Friday

March 18, 2024 | globenewswire.com

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

March 11, 2024 | msn.com

West Virginia State Police will be conducting a Sobriety Checkpoint

See More Headlines

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/22/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CKPT
CUSIP: N/A
CIK: 1651407
Web: www.checkpointtx.com
Phone: (781) 652-4500
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $22.60
High Stock Price Target: $47.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,241.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,850,000.00
Net Margins: -50,336.89%
Pretax Margin: -50,336.89%
Return on Equity: N/A
Return on Assets: -950.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.29
Quick Ratio: 0.29

Sales & Book Value

Annual Sales: $103,000.00
Price / Sales: 583.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.47) per share
Price / Book: -3.59

Miscellaneous

Outstanding Shares: 35,686,000
Free Float: 34,937,000
Market Cap: $60.13 million
Optionable: Optionable
Beta: 0.99

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. James F. Oliviero III (Age 48)
C.F.A., President, CEO & Director
Comp: $891k
Mr. William Garrett Gray (Age 37)
CFO, Corporate Secretary & Treasurer
Comp: $365.75k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CKPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings or view top-rated stocks.
What is Checkpoint Therapeutics' stock price target for 2024?: 5 brokerages have issued 1-year target prices for Checkpoint Therapeutics' stock. Their CKPT share price targets range from $4.00 to $47.00. On average, they predict the company's share price to reach $22.60 in the next year. This suggests a possible upside of 1,214.0% from the stock's current price.
View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts.
How have CKPT shares performed in 2024?: Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of the year. Since then, CKPT stock has decreased by 24.9% and is now trading at $1.72.
View the best growth stocks for 2024 here.
When is Checkpoint Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our CKPT earnings forecast.

How were Checkpoint Therapeutics' earnings last quarter?: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) released its earnings results on Friday, March, 22nd. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million.
When did Checkpoint Therapeutics' stock split?: Checkpoint Therapeutics's stock reverse split on the morning of Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Checkpoint Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).
How do I buy shares of Checkpoint Therapeutics?: Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CKPT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

Checkpoint Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Checkpoint Therapeutics Stock (NASDAQ:CKPT)

CKPT Stock Price History

CKPT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CKPT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™